Yun-Xing Cheng
AstraZeneca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yun-Xing Cheng.
Bioorganic & Medicinal Chemistry Letters | 2008
Daniel Page; Elise Balaux; Luc Boisvert; Ziping Liu; Claire Milburn; Maxime Tremblay; Zhongyong Wei; Simon Woo; Xuehong Luo; Yun-Xing Cheng; Hua Yang; Sanjay Srivastava; Fei Zhou; William Brown; Miroslaw Tomaszewski; Christopher Walpole; Leila Hodzic; Stephane St-Onge; Claude Godbout; Dominic Salois; Keymal Payza
The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.
Organic Letters | 2010
Xuehong Luo; Etienne Chénard; Peter Martens; Yun-Xing Cheng; Miroslaw Tomaszewski
A practical and highly efficient route to the synthesis of pharmaceutically interesting quinoxalinone scaffolds is reported. The key step involves an intramolecular palladium-catalyzed N-arylation under microwave irradiation. The developed methodology tolerates a variety of bromoanilides to afford a diverse collection of bicyclic and polycyclic quinoxalinones in high yield.
Bioorganic & Medicinal Chemistry Letters | 2012
Yun-Xing Cheng; Mehrnaz Pourashraf; Xuehong Luo; Sanjay Srivastava; Christopher Walpole; Dominic Salois; Stephane St-Onge; Kemal Payza; Etienne Lessard; Xiao Hong Yu; Miroslaw Tomaszewski
An oral, peripherally restricted CB1/CB2 agonist could provide an interesting approach to treat chronic pain by harnessing the analgesic properties of cannabinoids but without the well-known central side effects. γ-Carbolines are a novel class of potent mixed CB1/CB2 agonists characterized by attractive physicochemical properties including high aqueous solubility. Optimization of the series has led to the discovery of 29, which has oral activity in a rat inflammatory pain model and limited brain exposure at analgesic doses, consistent with a lower risk of CNS-mediated tolerability issues.
Archive | 2006
Yun-Xing Cheng; Miroslaw Tomaszewski
Archive | 2007
Yun-Xing Cheng; Shujuan Jin; Mehrnaz Pourashraf; Miroslaw Tomaszewski
Archive | 2007
Yun-Xing Cheng; Miroslaw Tomaszewski; Hua Yang
Archive | 2008
Yun-Xing Cheng; Xuehong Luo; Vijayaratnam Santhakumar; Miroslaw Tomaszewski
Archive | 2008
Yun-Xing Cheng; Xuehong Luo; Vijayaratnam Santhakumar; Miroslaw Tomaszewski
Archive | 2007
Yun-Xing Cheng; Xuehong Luo; Miroslaw Tomaszewski
Archive | 2009
Yun-Xing Cheng; Vijayaratnam Santhakumar; Miroslaw Tomaszewski